CK Life Sciences International (Holdings), Inc. (LSI) AI Stock Analysis

CK Life Sciences International (Holdings), Inc.

(Frankfurt:LSI)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Segment diversificationOperating across environmental and health-related segments gives CK Life Sciences more than one avenue for revenue generation. Pest-management products and services can provide recurring demand, while health products add a separate commercialization channel and reduce reliance on a single offering.

Negative Factors

Margin and earnings deteriorationRevenue was broadly flat, declining about 1.5% in 2025, while gross margin collapsed to about 14.5% from 30.6% and the company moved into operating losses. This signals weak earnings quality and makes recovery dependent on restoring economics, not simply maintaining sales.

CK Life Sciences International (Holdings), Inc. (LSI) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 4.71B
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -73.1
Beta (1Y): 1.14
Revenue Growth: -6.59%
EPS Growth: 79.41%
Country: Germany
Employees: 1,920
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

CK Life Sciences International (Holdings), Inc. Business Overview & Revenue Model

Company Description

CK Life Sciences International (Holdings), Inc. operates as an investment company, which engages in the business of research and development, manufacturing, commercialization, marketing and selling of products and assets in nutraceuticals, pharmaceut...

CK Life Sciences International (Holdings), Inc. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:LSI against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HK:2096	68Neutral	HKD 26.04B	14.11	16.54%	2.04%	27.24%	79.48%
HK:2696	65Neutral	HKD 26.75B	26.18	20.41%	―	32.63%	8.74%
HK:1177	61Neutral	HKD 85.83B	30.75	7.56%	2.49%	14.57%	-31.09%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HK:1877	41Neutral	HKD 30.07B	-69.15	-7.23%	―	35.82%	54.40%
HK:1672	30Underperform	HKD 5.15B	-7.05	-28.15%	―	-59.39%	-130.04%

* Healthcare Sector Average

Performance Comparison

DE:LSI and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:LSI	CK Life Sciences International (Holdings), Inc.	0.05	-0.04	-44.33%
HK:1177	Sino Biopharmaceutical	4.82	-2.13	-30.64%
HK:1672	Ascletis Pharma, Inc.	4.90	-4.91	-50.05%
HK:1877	Shanghai Junshi Biosciences Co., Ltd. Class H	15.26	-11.44	-42.85%
HK:2096	Simcere Pharmaceutical Group Limited	10.14	-2.85	-21.96%
HK:2696	Shanghai Henlius Biotech, Inc. Class H	49.06	-20.04	-29.00%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

CK Life Sciences International (Holdings), Inc. AI Stock Analysis